​ Adjuvant chemoradiotherapy increases five-year overall survival and failure-free survival compared with radiotherapy alone for women with high-risk endometrial cancer, report the researchers of the phase 3 PORTEC-3 trial in their updated analysis, which has now been published in The Lancet Oncology . Around 15% to 20% of patients with endometrial cancer are considered to have high-risk endometrial cancer, defined as endometrioid endometrial cancer stage 1, grade 3 with deep invasion; stage II ...

​ Because endometrial carcinoma is a heterogeneous disease, it is often difficult to treat, and women diagnosed with advanced disease are at risk for local and systemic recurrence. When researchers tested platinum-based chemotherapy plus radiation therapy against chemotherapy alone in patients with stage III or IVA endometrial carcinoma to see which treatment improved outcomes the most, they discovered that chemoradiotherapy did not improve outcomes more so than chemotherapy alone. This study, r...

​ A phase 1/2 clinical trial reports that stereotactic body radiotherapy (SBRT) is well tolerated by patients with centrally located early-stage non-small cell lung cancer (NSCLC). A high-dose ablative radiotherapy, SBRT is a standard, generally well-tolerated treatment for patients with inoperable, node-negative NSCLC. It has not previously been studied in patients with centrally located early-stage NSCLC because these patients are at increased risk of experiencing toxicity from high-dose ablat...

​ A new study reports that compared with photon radiotherapy, carbon ion radiotherapy reduces the risk of subsequent primary tumors in patients with localized prostate cancer. "The risk of subsequent primary cancers in patients with prostate cancer after treatment with photon radiotherapy is small in absolute numbers, but it is higher than that after surgical treatment," explain the authors of the study, which was published in The Lancet Oncology . "Carbon ion radiotherapy has a theoretically lo...

A phase 3 clinical trial reports that adding docetaxel to a standard regimen consisting of radiotherapy and long-term androgen suppression (AS) therapy improves outcomes for men with high-risk nonmetastatic prostate cancer. In the United States, prostate cancer is the second leading cause of cancer-related death among men. Of the 20% of patients whose prostate cancer is considered high risk, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are c...